Leerink Partners analyst David Risinger maintains $Johnson & Johnson (JNJ.US)$ with a buy rating, and sets the target price at $182.
According to TipRanks data, the analyst has a success rate of 62.9% and a total average return of 15.7% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Johnson & Johnson (JNJ.US)$'s main analysts recently are as follows:
Following a Q3 report which was described as being broadly consistent with projections, with the Pharma segment outperforming and the Medtech segment underperforming expectations, there were slight revisions made to the anticipated figures.
Following the third-quarter report, there's an optimistic perspective on Johnson & Johnson due in part to the progression of the talc litigation settlement proposal. Additionally, the company has successfully completed several acquisitions in the medical technology sector and provided commentary setting expectations for 2025, reinforcing a positive outlook on the stock.
Johnson & Johnson outperformed expectations with a 5.6% underlying growth excluding Covid impact, largely propelled by the strength in Innovative Medicine, albeit with MedTech experiencing seasonal patterns and challenges in the Asia Pacific region. Post Q3 results, it's evident that the company is making significant operational strides, with a focus on executing its pipeline development effectively.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
Leerink Partners分析師David Risinger維持$強生 (JNJ.US)$買入評級,目標價182美元。
根據TipRanks數據顯示,該分析師近一年總勝率為62.9%,總平均回報率為15.7%。
此外,綜合報道,$強生 (JNJ.US)$近期主要分析師觀點如下:
根據描述與預期基本一致的第三季度報告顯示,製藥業務表現優異,醫療科技板塊的表現未達預期,對預期數據進行了輕微修訂。
根據第三季度報告,投資者對強生公司持樂觀態度,部分原因是滑石訴訟和解提議的進展。此外,該公司成功完成了幾項醫療科技板塊的收購,並就2025年業績發佈了評論,強化了股票的積極前景。
強生公司在第三季度展現出色,除新冠影響外實現5.6%的基礎增長,主要得益於創新藥品板塊的實力,儘管醫療科技板塊經歷了季節性波動和亞太地區的挑戰。第三季度後的表現顯示,公司正在取得重大的運營進展,注重有效執行其研發管線計劃。
提示:
TipRanks為獨立第三方,提供金融分析師的分析數據,並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議,僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級,分析師星級代表分析師所有推薦的過往表現,通過分析師的總勝率和平均回報率综合計算得出,星星越多,則該分析師過往表現越優異,最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否,取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合,並根據評級變化對組合進行調整,在近一年中該投資組合所獲得的回報率。